Maiko Abumiya

Influence of UGT1A1 *6, *27, and *28 Polymorphisms on Nilotinib-induced Hyperbilirubinemia in Japanese Patients with Chronic Myeloid Leukemia

Maiko Abumiya, Naoto Takahashi, Takenori Niioka et al. · Drug Metabolism and Pharmacokinetics · 2014 · 41 citations

Medicine, Genetics, Pharmacology +12

Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes

Takenori Niioka, Naohito Fujishima, Maiko Abumiya et al. · Therapeutic Drug Monitoring · 2017 · 34 citations

Pharmacy, Pharmacokinetics, Pharmacology +10

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia

A. Mita, Maiko Abumiya, Masatomo Miura et al. · Experimental Hematology and Oncology · 2018 · 33 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients

Maiko Abumiya, Masatomo Miura, Naoto Takahashi · Leukemia Research · 2017 · 27 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib

Naoto Takahashi, Masatomo Miura, Jun Kuroki et al. · Biomarker Research · 2014 · 25 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12